Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)
CUSIP: 004890109
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 38,870,454
- Total 13F shares
- 23,250,351
- Share change
- -129,687
- Total reported value
- $139,966,100
- Price per share
- $6.02
- Number of holders
- 60
- Value change
- -$971,335
- Number of buys
- 24
- Number of sells
- 18
Quarterly Holders Quick Answers
What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 004890109:
Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
21%
|
8,340,508
|
$58,383,556 | — | 30 Sep 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
14%
|
5,360,858
|
$37,526,006 | — | 30 Sep 2024 | |
| Kristina Masson |
3/4/5
|
EVP - Business Operations, Director |
—
class O/S missing
|
2,819,375
|
$19,792,013 | — | 14 Aug 2024 | |
| Chione Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,848,632
|
$16,741,549 | — | 26 Jun 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
5.5%
|
2,140,628
|
$14,984,396 | — | 30 Sep 2024 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
5.5%
|
2,122,605
|
$14,858,235 | — | 30 Sep 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.3%
|
888,130
|
$6,216,910 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.1%
|
809,859
|
$5,669,013 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
2%
|
786,982
|
$5,508,874 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.6%
|
637,538
|
$4,462,766 | — | 30 Sep 2024 | |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
888,130
|
$3,863,366 | — | 17 Nov 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.78%
|
302,103
|
$2,115,202 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.58%
|
225,896
|
$1,581,272 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.51%
|
198,168
|
$1,387,176 | — | 30 Sep 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
0.3%
|
116,757
|
$817,299 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.3%
|
116,253
|
$813,771 | — | 30 Sep 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.29%
|
112,414
|
$786,898 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.27%
|
105,398
|
$737,786 | — | 30 Sep 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.2%
|
79,249
|
$554,743 | — | 30 Sep 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.2%
|
76,981
|
$538,867 | — | 30 Sep 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.14%
|
52,885
|
$370,195 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
45,900
|
$321,300 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.1%
|
39,750
|
$278,250 | — | 30 Sep 2024 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
37,727
|
$264,089 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.09%
|
35,914
|
$251,398 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.09%
|
33,991
|
$237,937 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.09%
|
33,306
|
$233,142 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.08%
|
30,824
|
$215,768 | — | 30 Sep 2024 | |
| Trexquant Investment LP |
13F
|
Company |
0.08%
|
30,383
|
$212,681 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.08%
|
29,963
|
$209,741 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
29,509
|
$206,563 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.07%
|
25,779
|
$180,453 | — | 30 Sep 2024 | |
| EXCHANGE TRADED CONCEPTS, LLC |
13F
|
Company |
0.05%
|
20,348
|
$142,436 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.05%
|
17,760
|
$124,320 | — | 30 Sep 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.04%
|
15,402
|
$107,814 | — | 30 Sep 2024 | |
| Marex Group plc |
13F
|
Company |
0.03%
|
13,187
|
$92,309 | — | 30 Sep 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
11,216
|
$78,512 | — | 30 Sep 2024 | |
| AAF Wealth Management, LLC |
13F
|
Company |
0.03%
|
10,678
|
$74,746 | — | 30 Sep 2024 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.02%
|
6,471
|
$45,297 | — | 30 Sep 2024 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.02%
|
6,316
|
$44,212 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
5,662
|
$39,634 | — | 30 Sep 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
5,422
|
$37,954 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
4,755
|
$33,285 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
0.01%
|
2,581
|
$18,067 | — | 30 Sep 2024 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
2,314
|
$16,198 | — | 30 Sep 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
1,277
|
$9,000 | — | 30 Sep 2024 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0%
|
856
|
$5,992 | — | 30 Sep 2024 | |
| Legal & General Group Plc |
13F
|
Company |
0%
|
839
|
$5,873 | — | 30 Sep 2024 | |
| STRS OHIO |
13F
|
Company |
0%
|
800
|
$5,600 | — | 30 Sep 2024 | |
| Ameritas Investment Partners, Inc. |
13F
|
Company |
0%
|
695
|
$4,865 | — | 30 Sep 2024 |
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q4 2024
As of 31 Dec 2024,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by
60 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,250,351 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, BlackRock, Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, MARSHALL WACE, LLP, ACORN CAPITAL ADVISORS, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
61
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
51
Q4 2024 holders
60
Holder diff
9
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.